- Home
- CNR vs PRCT Comparison
CNR vs PRCT Comparison
Compare CNR & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNR
- PRCT
- Stock Information
- Founded
- CNR 1864
- PRCT 2009
- Country
- CNR United States
- PRCT United States
- Employees
- CNR N/A
- PRCT N/A
- Industry
- CNR Coal Mining
- PRCT Medical Specialities
- Sector
- CNR Energy
- PRCT Health Care
- Exchange
- CNR Nasdaq
- PRCT Nasdaq
- Market Cap
- CNR 3.7B
- PRCT 3.2B
- IPO Year
- CNR N/A
- PRCT 2021
- Fundamental
- Price
- CNR $69.63
- PRCT $60.22
- Analyst Decision
- CNR Strong Buy
- PRCT Strong Buy
- Analyst Count
- CNR 4
- PRCT 7
- Target Price
- CNR $99.25
- PRCT $90.00
- AVG Volume (30 Days)
- CNR 846.2K
- PRCT 832.3K
- Earning Date
- CNR 08-15-2025
- PRCT 07-31-2025
- Dividend Yield
- CNR 0.29%
- PRCT N/A
- EPS Growth
- CNR N/A
- PRCT N/A
- EPS
- CNR 3.30
- PRCT N/A
- Revenue
- CNR $2,663,948,000.00
- PRCT $249,121,000.00
- Revenue This Year
- CNR $91.77
- PRCT $47.40
- Revenue Next Year
- CNR $9.51
- PRCT $31.55
- P/E Ratio
- CNR $21.08
- PRCT N/A
- Revenue Growth
- CNR 11.29
- PRCT 59.36
- 52 Week Low
- CNR $58.19
- PRCT $47.04
- 52 Week High
- CNR $134.59
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- CNR N/A
- PRCT 52.43
- Support Level
- CNR N/A
- PRCT $58.34
- Resistance Level
- CNR N/A
- PRCT $61.43
- Average True Range (ATR)
- CNR 0.00
- PRCT 2.61
- MACD
- CNR 0.00
- PRCT -0.37
- Stochastic Oscillator
- CNR 0.00
- PRCT 38.21
About CNR Core Natural Resources Inc. Common Stock
Core Natural Resources Inc is a producer and exporter of coal. The company owns and operates longwall mining operations in the nation and export terminals on the Eastern seaboard. The principal activity involves mining, preparation, and marketing of thermal coal, sold to power generators.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.